Navigation Links
Advanced Life Sciences to Host Second Quarter 2010 Conference Call and Live Webcast
Date:8/4/2010

CHICAGO, Aug. 4 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) today announced that it will host a conference call and live webcast at 9:00 a.m. Eastern Time on Wednesday, August 11, 2010 to discuss the Company's second quarter 2010 financial results. Michael T. Flavin, Ph.D., Chairman & Chief Executive Officer, and other members of the management team will also present an update on the Company. A press release reporting the second quarter 2010 financial results will be issued before the U.S. stock markets open on Wednesday, August 11, 2010.

(Logo: http://photos.prnewswire.com/prnh/20080218/ALSLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website at www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 888.713.4214 (domestic) or 617.213.4866 (international). The passcode for the conference call is 88373836. A replay of the conference call will be available until August 18, 2010. Callers may access the telephone replay by dialing 888.286.8010 (domestic) or 617.801.6888 (international), passcode 91902424. Investors are advised to dial into the call at least ten minutes prior to the call to register. Participants may pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=PVR4PNXWM. Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection.

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, clinical trials, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Advanced Data Systems Partners with 1450 and Dr. Ravi Venkataraman to Offer a Free EHR Webinar for Speech Recognition
2. MAQUET Cardiovascular Launches Advanced VASOVIEW Technology for Endoscopic Vessel Harvesting Procedures in Cardiac Surgery
3. Cancer Patients in Scotland Gain Access to Advanced RapidArc Radiotherapy Treatments from Varian Medical Systems
4. ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc.
5. Advanced Life Sciences Submits Updated Special Protocol Assessment to FDA for Restanza in Community Acquired Bacterial Pneumonia
6. MediPurpose® Announces U.S. Distribution Agreement With Pharmaplast, Egyptian Advanced Wound Care OEM
7. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
8. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
9. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
10. New Georgia Advanced Surgery Center Provides Women Many Unique Benefits
11. Advanced Life Sciences Expands Collaboration with U.S. Government to Study Restanza(TM) as Treatment for Sexually Transmitted Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 4, 2016 Global Insulin ... profiling 09 key companies and supported with 272 ... in-depth study on the current state of the ... the industry including definitions, classifications, applications and industry ... provided for the international market including development history, ...
(Date:5/3/2016)... 3, 2016 ACME Markets, ... and Delaware County Councilman Dave White ... in all ACME pharmacies across ... Control and Prevention (CDC), naloxone has saved 26,463 lives nationwide over ... Delaware County were authorized to administer naloxone ...
(Date:5/3/2016)... May 3, 2016 Pharmaceutical giant ... million to a woman who says its talc-based powder ... Gloria Ristesund $5 million in compensatory damages ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , This ... the company. In February, the same court awarded $72 ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Cirius, a provider of cloud-based ... Secure Messaging platform, which includes secure, private messaging, large file sharing, secure e-signatures, ... of patents around innovative features for securing, tracking, and controlling messages for organizations ...
(Date:5/4/2016)... ... May 04, 2016 , ... Somnoware Healthcare ... today announced it has secured $9 million in Series A funding led by ... investment will be used by Somnoware to further fulfill its mission to connect, ...
(Date:5/4/2016)... Palm City, Florida (PRWEB) , ... May 04, ... ... providers of cold therapy products, announced today the introduction of the innovative newly ... for post operative hip replacement patients. The plush design enhances comfort and enables ...
(Date:5/4/2016)... ... 04, 2016 , ... a2z, Inc. is pleased to announce ... for Enterostomal Therapy (CAET) will be utilizing powerful and innovative technology solutions to ... exhibitors for the 2016 WOCN Society & CAET Joint Conference—which is the largest ...
(Date:5/4/2016)... ... May 04, 2016 , ... Washington Wellness Center today ... central New Jersey residents. What started out as an idea to provide a ... integrated approach to healthcare. , Developed by Dr. David Swanekamp, Chiropractic Physician , ...
Breaking Medicine News(10 mins):